Which has higher valuation & earnings, IMA or HUMA?

Humacyte has higher revenue and earnings than ImageneBio. Humacyte is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImageneBio $800K 76.25 -$45.35M -$5.79 N/A Humacyte $2.04M 164.88 -$40.83M -$0.57 N/A

Is IMA or HUMA more profitable?

ImageneBio has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. ImageneBio's return on equity of -38.96% beat Humacyte's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Humacyte -4,836.06% -2,914.18% -89.45%

Which has better valuation and earnings, ALEC or IMA?

ImageneBio has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alector $21.05M 9.84 -$142.93M -$1.19 N/A ImageneBio $800K 76.25 -$45.35M -$5.79 N/A

Is ALEC or IMA more profitable?

ImageneBio has a net margin of 0.00% compared to Alector's net margin of -680.83%. ImageneBio's return on equity of -38.96% beat Alector's return on equity. Company Net Margins Return on Equity Return on Assets Alector -680.83% -295.17% -40.95% ImageneBio N/A -38.96% -34.60%

Is NERV or IMA more profitable?

Minerva Neurosciences' return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% ImageneBio N/A -38.96% -34.60%

Is IMA or SGMT more profitable?

Sagimet Biosciences' return on equity of -37.57% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Sagimet Biosciences N/A -37.57% -35.52%

ImageneBio (IMA) Competitors

$5.73 +0.28 (+5.12%)

As of 02:55 PM Eastern

Compare

IMA vs. HUMA, ALEC, NERV, LENZ, and SGMT

Should you buy ImageneBio stock or one of its competitors? MarketBeat compares ImageneBio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImageneBio include Humacyte (HUMA), Alector (ALEC), Minerva Neurosciences (NERV), LENZ Therapeutics (LENZ), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.

How does ImageneBio compare to Humacyte?

ImageneBio (NASDAQ:IMA) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 44.7% of Humacyte shares are held by institutional investors. 5.9% of ImageneBio shares are held by company insiders. Comparatively, 3.1% of Humacyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ImageneBio has a net margin of 0.00% compared to Humacyte's net margin of -4,836.06%. ImageneBio's return on equity of -38.96% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Humacyte	-4,836.06%	-2,914.18%	-89.45%

ImageneBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market.

In the previous week, Humacyte had 2 more articles in the media than ImageneBio. MarketBeat recorded 2 mentions for Humacyte and 0 mentions for ImageneBio. Humacyte's average media sentiment score of 1.04 beat ImageneBio's score of 0.94 indicating that Humacyte is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
Humacyte	Positive

Humacyte has higher revenue and earnings than ImageneBio. Humacyte is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	76.25	-$45.35M	-$5.79	N/A
Humacyte	$2.04M	164.88	-$40.83M	-$0.57	N/A

ImageneBio presently has a consensus price target of $26.50, suggesting a potential upside of 362.64%. Humacyte has a consensus price target of $6.43, suggesting a potential upside of 324.33%. Given ImageneBio's higher probable upside, research analysts plainly believe ImageneBio is more favorable than Humacyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Humacyte beats ImageneBio on 9 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Alector?

Alector (NASDAQ:ALEC) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

Alector presently has a consensus target price of $3.63, suggesting a potential upside of 94.37%. ImageneBio has a consensus target price of $26.50, suggesting a potential upside of 362.64%. Given ImageneBio's higher possible upside, analysts plainly believe ImageneBio is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

In the previous week, Alector had 6 more articles in the media than ImageneBio. MarketBeat recorded 6 mentions for Alector and 0 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.94 beat Alector's score of 0.93 indicating that ImageneBio is being referred to more favorably in the news media.

Company	Overall Sentiment
Alector	Positive
ImageneBio	Positive

Alector has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market.

ImageneBio has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	9.84	-$142.93M	-$1.19	N/A
ImageneBio	$800K	76.25	-$45.35M	-$5.79	N/A

ImageneBio has a net margin of 0.00% compared to Alector's net margin of -680.83%. ImageneBio's return on equity of -38.96% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
ImageneBio	N/A	-38.96%	-34.60%

85.8% of Alector shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 8.3% of Alector shares are held by company insiders. Comparatively, 5.9% of ImageneBio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

ImageneBio beats Alector on 10 of the 17 factors compared between the two stocks.

How does ImageneBio compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Minerva Neurosciences' return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
ImageneBio	N/A	-38.96%	-34.60%

In the previous week, Minerva Neurosciences had 1 more articles in the media than ImageneBio. MarketBeat recorded 1 mentions for Minerva Neurosciences and 0 mentions for ImageneBio. Minerva Neurosciences' average media sentiment score of 1.09 beat ImageneBio's score of 0.94 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Minerva Neurosciences	Positive
ImageneBio	Positive

Minerva Neurosciences presently has a consensus price target of $10.50, suggesting a potential upside of 118.30%. ImageneBio has a consensus price target of $26.50, suggesting a potential upside of 362.64%. Given ImageneBio's higher possible upside, analysts plainly believe ImageneBio is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Minerva Neurosciences has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, ImageneBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

ImageneBio has higher revenue and earnings than Minerva Neurosciences. ImageneBio is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
ImageneBio	$800K	76.25	-$45.35M	-$5.79	N/A

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 5.9% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

ImageneBio beats Minerva Neurosciences on 8 of the 14 factors compared between the two stocks.

How does ImageneBio compare to LENZ Therapeutics?

ImageneBio (NASDAQ:IMA) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, LENZ Therapeutics' average media sentiment score of 1.89 beat ImageneBio's score of 0.94 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
LENZ Therapeutics	Very Positive

ImageneBio has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	76.25	-$45.35M	-$5.79	N/A
LENZ Therapeutics	$19.09M	11.75	-$82.13M	-$3.60	N/A

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by company insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ImageneBio has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. ImageneBio's return on equity of -38.96% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

ImageneBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

ImageneBio currently has a consensus target price of $26.50, indicating a potential upside of 362.64%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 316.49%. Given ImageneBio's higher probable upside, analysts plainly believe ImageneBio is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ImageneBio beats LENZ Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ImageneBio compare to Sagimet Biosciences?

ImageneBio (NASDAQ:IMA) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

75.0% of ImageneBio shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 5.9% of ImageneBio shares are owned by company insiders. Comparatively, 14.7% of Sagimet Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Sagimet Biosciences had 1 more articles in the media than ImageneBio. MarketBeat recorded 1 mentions for Sagimet Biosciences and 0 mentions for ImageneBio. ImageneBio's average media sentiment score of 0.94 beat Sagimet Biosciences' score of 0.93 indicating that ImageneBio is being referred to more favorably in the media.

Company	Overall Sentiment
ImageneBio	Positive
Sagimet Biosciences	Positive

ImageneBio has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	$800K	76.25	-$45.35M	-$5.79	N/A
Sagimet Biosciences	$2M	114.75	-$51.04M	-$1.34	N/A

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 362.64%. Sagimet Biosciences has a consensus price target of $25.75, indicating a potential upside of 265.56%. Given ImageneBio's higher possible upside, equities analysts clearly believe ImageneBio is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Sagimet Biosciences' return on equity of -37.57% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Sagimet Biosciences	N/A	-37.57%	-35.52%

ImageneBio has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, suggesting that its share price is 241% more volatile than the broader market.

Summary

Sagimet Biosciences beats ImageneBio on 10 of the 16 factors compared between the two stocks.

Get ImageneBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMA vs. The Competition

Export

Metric	ImageneBio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$61.00M	$3.33B	$6.42B	$12.48B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.99	18.86	23.85	24.39
Price / Sales	76.25	319.25	520.29	116.29
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	0.48	6.82	10.04	6.74
Net Income	-$45.35M	$24.09M	$3.56B	$337.03M
7 Day Performance	-3.41%	-2.69%	-1.09%	0.13%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-64.38%	48.33%	28.56%	34.29%

ImageneBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMA ImageneBio	3.0706 of 5 stars	$5.73 +5.1%	$26.50 +362.6%	-66.4%	$61.01M	$800K	N/A	70
HUMA Humacyte	4.062 of 5 stars	$1.13 +1.4%	$7.57 +573.0%	-46.2%	$249.77M	$2.04M	N/A	150	Analyst Forecast
ALEC Alector	3.4118 of 5 stars	$2.25 +2.5%	$3.63 +61.5%	+19.9%	$249.25M	$18.42M	N/A	270	Insider Trade
NERV Minerva Neurosciences	2.6306 of 5 stars	$5.33 +2.0%	$10.50 +97.2%	+166.7%	$248.09M	N/A	N/A	9	Positive News
LENZ LENZ Therapeutics	3.1726 of 5 stars	$7.78 +0.3%	$29.80 +283.2%	-76.5%	$244.44M	$19.09M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMA) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImageneBio (IMA) Competitors

IMA vs. HUMA, ALEC, NERV, LENZ, and SGMT

How does ImageneBio compare to Humacyte?

Summary

How does ImageneBio compare to Alector?

Summary

How does ImageneBio compare to Minerva Neurosciences?

Summary

How does ImageneBio compare to LENZ Therapeutics?

Summary

How does ImageneBio compare to Sagimet Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImageneBio (IMA) Competitors

IMA vs. HUMA, ALEC, NERV, LENZ, and SGMT

How does ImageneBio compare to Humacyte?

Do institutionals and insiders hold more shares of IMA or HUMA?

Is IMA or HUMA more profitable?

Which has more risk & volatility, IMA or HUMA?

Does the media prefer IMA or HUMA?

Which has higher valuation & earnings, IMA or HUMA?

Do analysts rate IMA or HUMA?

Summary

How does ImageneBio compare to Alector?

Do analysts rate ALEC or IMA?

Does the media refer more to ALEC or IMA?

Which has more volatility & risk, ALEC or IMA?

Which has better valuation and earnings, ALEC or IMA?

Is ALEC or IMA more profitable?

Do insiders and institutionals believe in ALEC or IMA?

Summary

How does ImageneBio compare to Minerva Neurosciences?

Is NERV or IMA more profitable?

Does the media refer more to NERV or IMA?

Do analysts prefer NERV or IMA?

Which has more risk & volatility, NERV or IMA?

Which has better earnings and valuation, NERV or IMA?

Do insiders & institutionals hold more shares of NERV or IMA?

Summary

How does ImageneBio compare to LENZ Therapeutics?

Does the media prefer IMA or LENZ?

Which has stronger earnings & valuation, IMA or LENZ?

Do institutionals and insiders believe in IMA or LENZ?

Is IMA or LENZ more profitable?

Which has more volatility & risk, IMA or LENZ?

Do analysts prefer IMA or LENZ?

Summary

How does ImageneBio compare to Sagimet Biosciences?

Do insiders and institutionals believe in IMA or SGMT?

Does the media prefer IMA or SGMT?

Which has better valuation & earnings, IMA or SGMT?

Do analysts prefer IMA or SGMT?

Is IMA or SGMT more profitable?

Which has more volatility and risk, IMA or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMA vs. The Competition

ImageneBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools